Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LN-145
LN-145/LN-144 · 1 trial · 5 indications
To evaluate the safety and tolerability of the TIL regimen that occurs from the start of TIL infusion and up to 30 days after TIL infusion per CTCAE.
| Arm | Type | Description |
|---|---|---|
| Rhabdomyosarcoma (RMS) | EXPERIMENTAL | - |
| Ewing Sarcoma (EWS) | EXPERIMENTAL | - |
| Primary Central Nervous System Tumor | EXPERIMENTAL | - |
| Melanoma | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LN-145/LN-144 | BIOLOGICAL | A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. |
Inclusion Criteria: 1. Participant is ≥ 8 kg and ≤ 21 years of age at the time of informed consent and assent. 2. Histologically or cytologically confirmed recurrent or refractory solid tumor (Rhabdomyosarcoma, Ewing sarcoma, primary CNS malignancies, melanoma) after standard therapy which has fail...
LN-145 is an investigational autologous tumor infiltrating lymphocyte therapy being studied for multiple cancers, including soft tissue sarcoma, metastatic non-small cell lung cancer, cutaneous squamous cell carcinoma, and squamous cell carcinoma of the head and neck. It is developed by Iovance Biotherapeutics and is currently in Phase 2 clinical trials.
LN-145 is a tumor infiltrating lymphocyte therapy, not a monoclonal antibody as sometimes categorized. It uses a patient's own immune cells that have infiltrated their tumor, which are then expanded and infused back to attack the cancer. The therapy targets tumor cells by harnessing the patient's immune system.
LN-145 is developed by Iovance Biotherapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker IOVA. The company is focused on developing novel cancer immunotherapies based on tumor infiltrating lymphocytes.
LN-145 is in Phase 2 clinical development for several indications. It has received accelerated approval designation from the FDA, but it remains investigational and is not yet fully approved. Clinical trials are ongoing or completed across multiple cancer types.
LN-145 is being studied in several trials, including NCT03083873 for squamous cell carcinoma of the head and neck (completed, Phase 2), NCT04614103 for metastatic non-small cell lung cancer (recruiting, Phase 2), NCT06566092 for pediatric cancers including soft tissue sarcoma (active, Phase 1), and NCT07288073 for cutaneous squamous cell carcinoma (recruiting, Phase 2).
Yes, LN-145 is also known as LN-145/LN-144. This naming convention is used in clinical trial documentation, particularly in the study NCT03083873, which evaluates LN-145/LN-145-S1 autologous tumor infiltrating lymphocytes for the treatment of squamous cell carcinoma of the head and neck.